INGE HANSCHU: Open Payments
NPI 1023261450 · ROYAL OAK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$690 in 31 payments from 12 companies in 2025. Trend: 2023 $8,148 · 2024 $3,009 · 2025 $690
Food & beverage: $690
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $181 |
| Janssen Biotech, Inc. | 6 | $119 |
| EVOKE PHARMA, INC. | 1 | $114 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Ardelyx, Inc. | 1 | $23 |
| Celltrion USA Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
Products named: TREMFYA, GIMOTI, SKYRIZI, DUPIXENT, RINVOQ, ENTYVIO, XIFAXAN, REZDIFFRA.
Industry payments across MI — which companies pay providers there.
